Corbus Pharmaceuticals Hldgs Inc (CRBP)

$10.24 -0.45 (-4.21%)
Market Cap 179.74M
Revenue (ttm) 0.00
Net Income (ttm) -40.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 261,200
Avg Vol 413,658
Day's Range N/A - N/A
Shares Out 17.55M
Stochastic %K 10%
Beta 2.71
Analysts Strong Sell
Price Target $42.33

Company Profile

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally re...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 963 0100
Fax: 617 663 6085
Address:
500 River Ridge Drive, Norwood, United States
shlomiko
shlomiko Dec. 5 at 7:44 PM
$CRBP After a massive ~30x dilution, CRBP at $0.34 is effectively the same as $10.25 pre-dilution. The chart doesn’t reflect the real value anymore. At this level, the stock looks heavily discounted. Do your own DD.
0 · Reply
birdmine
birdmine Dec. 5 at 7:38 PM
$CRBP I don’t think it’s going to hit 100k today.
0 · Reply
birdmine
birdmine Dec. 5 at 7:21 PM
$CRBP the volume on this stock is so low, it’s ridiculous!! They dilute it so much, now people are afraid to touch it!!
0 · Reply
birdmine
birdmine Dec. 5 at 5:05 PM
$CRBP I swear, this stock feels like such a scam!!
0 · Reply
shlomiko
shlomiko Dec. 5 at 5:28 AM
$CRBP
0 · Reply
birdmine
birdmine Dec. 4 at 12:26 PM
$CRBP
0 · Reply
shlomiko
shlomiko Dec. 4 at 9:23 AM
$CRBP
0 · Reply
shlomiko
shlomiko Dec. 3 at 3:20 PM
$CRBP
0 · Reply
birdmine
birdmine Dec. 3 at 1:51 PM
$CRBP I hope today doesn’t turn out trash!!
0 · Reply
birdmine
birdmine Dec. 2 at 9:07 PM
$CRBP they are speaking at a conference right now. Let’s how it triggers good momentum!!
0 · Reply
Latest News on CRBP
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 6, 2025, 8:00 AM EST - 4 weeks ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis

Nov 5, 2025, 11:42 AM EST - 4 weeks ago

Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis

Corbus Pharmaceuticals Announces Pricing of Public Offering

Oct 31, 2025, 2:40 AM EDT - 5 weeks ago

Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals Announces Proposed Public Offering

Oct 30, 2025, 4:31 PM EDT - 5 weeks ago

Corbus Pharmaceuticals Announces Proposed Public Offering

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript

Oct 20, 2025, 5:05 PM EDT - 6 weeks ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Oct 18, 2025, 3:00 AM EDT - 7 weeks ago

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Sep 16, 2025, 8:00 AM EDT - 2 months ago

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Corbus (CRBP) Q2 Loss Beats Estimates

Aug 5, 2025, 5:41 PM EDT - 4 months ago

Corbus (CRBP) Q2 Loss Beats Estimates

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Jun 25, 2025, 8:00 AM EDT - 5 months ago

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Jun 24, 2025, 4:05 PM EDT - 5 months ago

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

Jun 17, 2025, 3:42 PM EDT - 6 months ago

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 8:00 AM EDT - 7 months ago

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

May 19, 2025, 8:00 AM EDT - 7 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX QURE

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Mar 28, 2025, 8:00 AM EDT - 9 months ago

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Feb 14, 2025, 7:30 AM EST - 10 months ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Feb 11, 2025, 7:30 AM EST - 10 months ago

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Jan 28, 2025, 8:00 AM EST - 11 months ago

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:00 AM EST - 11 months ago

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Dec 9, 2024, 7:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Dec 3, 2024, 7:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Nov 11, 2024, 4:12 AM EST - 1 year ago

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Sep 23, 2024, 2:01 PM EDT - 1 year ago

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN GPCR SRRK VKTX

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 30, 2024, 8:50 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

Jun 3, 2024, 1:03 PM EDT - 1 year ago

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

Jun 1, 2024, 10:00 AM EDT - 1 year ago

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

May 30, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

May 23, 2024, 5:05 PM EDT - 1 year ago

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

May 9, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

May 1, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Mar 6, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Feb 28, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 9:50 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 2, 2024, 4:01 PM EST - 2 years ago

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Jan 30, 2024, 7:13 AM EST - 2 years ago

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

Jan 29, 2024, 2:17 PM EST - 2 years ago

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?

Jan 29, 2024, 7:18 AM EST - 2 years ago

Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Jan 26, 2024, 7:30 AM EST - 2 years ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

Jan 23, 2024, 8:00 AM EST - 2 years ago

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

Jan 9, 2024, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

Dec 18, 2023, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

shlomiko
shlomiko Dec. 5 at 7:44 PM
$CRBP After a massive ~30x dilution, CRBP at $0.34 is effectively the same as $10.25 pre-dilution. The chart doesn’t reflect the real value anymore. At this level, the stock looks heavily discounted. Do your own DD.
0 · Reply
birdmine
birdmine Dec. 5 at 7:38 PM
$CRBP I don’t think it’s going to hit 100k today.
0 · Reply
birdmine
birdmine Dec. 5 at 7:21 PM
$CRBP the volume on this stock is so low, it’s ridiculous!! They dilute it so much, now people are afraid to touch it!!
0 · Reply
birdmine
birdmine Dec. 5 at 5:05 PM
$CRBP I swear, this stock feels like such a scam!!
0 · Reply
shlomiko
shlomiko Dec. 5 at 5:28 AM
$CRBP
0 · Reply
birdmine
birdmine Dec. 4 at 12:26 PM
$CRBP
0 · Reply
shlomiko
shlomiko Dec. 4 at 9:23 AM
$CRBP
0 · Reply
shlomiko
shlomiko Dec. 3 at 3:20 PM
$CRBP
0 · Reply
birdmine
birdmine Dec. 3 at 1:51 PM
$CRBP I hope today doesn’t turn out trash!!
0 · Reply
birdmine
birdmine Dec. 2 at 9:07 PM
$CRBP they are speaking at a conference right now. Let’s how it triggers good momentum!!
0 · Reply
birdmine
birdmine Dec. 1 at 7:38 PM
$CRBP sigh
0 · Reply
Mavrick3
Mavrick3 Dec. 1 at 4:00 PM
$CRBP I had read there was news coming out in Dec. Does anyone know if and when news is being released this month?
0 · Reply
Cjstocks27
Cjstocks27 Nov. 24 at 5:54 PM
$CRBP Hoping for a push to $13 before end of week. $15 call contracts for 12/19 are looking promising 👀👀 let’s boost this thing 📈📈📈
0 · Reply
shlomiko
shlomiko Nov. 24 at 5:04 PM
$CRBP
0 · Reply
Hepacke
Hepacke Nov. 21 at 5:46 PM
$CRBP
0 · Reply
Wirralboy
Wirralboy Nov. 20 at 10:11 PM
$CRBP what’s the news after hours?
0 · Reply
shlomiko
shlomiko Nov. 20 at 2:37 PM
$CRBP
0 · Reply
MarkT87
MarkT87 Nov. 18 at 7:32 PM
$CRBP Lets Go!
0 · Reply
birdmine
birdmine Nov. 18 at 5:44 PM
$CRBP is begging for 13 today being greedy?!
2 · Reply
WoldanStanford
WoldanStanford Nov. 18 at 4:36 PM
$CODX $RVPH $ETHZ $CRBP $LNAI MY PERSONAL 1-5X baggers
0 · Reply
shlomiko
shlomiko Nov. 18 at 1:41 PM
$CRBP
0 · Reply
birdmine
birdmine Nov. 17 at 5:46 PM
$CRBP boy, they are trading within a tight range today!!
0 · Reply